References
- Murati A , BrecquevilleM, DevillierR, MozziconacciMJ, Gelsi-BoyerV, BirnbaumD. Myeloid malignancies: mutations, models and management. BMC Cancer12 , 304 (2012).
- Chase A , CrossNC. Aberrations of EZH2 in cancer. Clin. Cancer Res.17 , 2613–2618 (2011).
- Chung YR , SchatoffE, Abdel-WahabO. Epigenetic alterations in hematopoietic malignancies. Int. J. Hematol.96 , 413–427 (2012).
- Khan SN , JankowskaAM, MahfouzR et al. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia 27(6) , 1301–1309 (2013).
References
- Mak KS , FunnellAP, PearsonRC, CrossleyM. PU.1 and haematopoietic cell fate: dosage matters. Int. J. Cell Biol.2011 , 808524 (2011).
- Shen X , LiuY, HsuYJ et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol. Cell 32 , 491–502 (2008).
- Lee TI , JennerRG, BoyerLA et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125 , 301–313 (2006).
- Cheng JX , AnastasiJ, WatanabeK et al. Genome-wide profiling reveals epigenetic inactivation of the PU.1 pathway by histone H3 lysine 27 trimethylation in cytogenetically normal myelodysplastic syndrome. Leukemia 27(6) , 1291–1300 (2013).